Wednesday, 22 Jan 2020

You are here

Spondyloarthritis Affects Pregnancy Outcomes

A Danish registy has shown that the the prevalence of Spondyloarthritis (SpA) diagnosed prior to delivery has increased 5 fold in the last two decades and that SpA is associated with an increased risk of adverse pregnancy outcomes (APO).

Researchers used data and outcomes from the Danish Medical Birth Register and 1,199,610 singleton pregnancies between 1997-2016. They analyzed those individuals identified as SpA or related subtypes (ankylosing spondylitis, psoriatic arthritis, reactive arthritis, arthritis associated with inflammatory bowel diseases, and undifferentiated SpA). 

Between 1997 and 2016 the prevalence of SpA diagnosed prior to labor increased from 0.1% in 1997 to 0.6% in 2016.

Comparing women without SpA to women with SpA, APOs were significantly increased for preterm birth (OR 1.56 [95% CI: 1.33-1.83]), elective cesarean section (OR: 1.44 [95% CI: 1.26-1.64]), emergency cesarean section OR 1.17 [95% CI: 1.04-1.33]), and use of epidural (OR 1.11 [95% CI: 1.02-1.20]).

The odds ratios for small for gestational age birth and preeclampsia were not increased for SpA women compared to controls.

There were no differences between the subtypes of SpA.

SpA women who become pregnant may be at increased risk for preterm birth or cesarean sections but not for preeclampsia or low gestational birth weight.  The increase in the observed prevalence of pregnancy in SpA may reflection changing attitudes by physicians and SpA patients. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.

Best of 2019 - SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.

Best of 2019 - ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axial Spondyloarthritis (nr-axSpA).

Upadacitinib Effective in Ankylosing Spondylitis

Lancet reports that the selective JAK1 inhibitor, upadacitinib, was effective when given to patients with active ankylosing spondylitis.

Secukinumab Improves Enthesitis

Secukinumabs (SEC) effect on enthesitis in psoriatic arthritis (PsA) was studied in the FUTURE 2 and 3 studies and SEC was shown significantly reduced enthesitis by more than 65% within 14 week.